Ally Therapeutics is a stealth-mode biotech company founded in 2019 which is dedicated to solving the immune response barrier for in vivo gene therapies. They are testing AAV vectors in cells and in animal models to determine therapeutic efficacy and immune responses. They spun the company out of the Church Lab at Harvard after raising $10M from a VC syndicate led by ARCH Venture Partners.